Iskandar Idris
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Iskandar Idris has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
Andrew Simm
Department of Diabetes & Endocrinology, Nottingham City Hospital, Nottingham, UK
2 shared publicationsD. J. Fernando
Department of Diabetes & Endocrinology, Sherwood Forest Hospitals Foundation Trust Mansfield UK
2 shared publicationsGraham Warren
2 shared publicationsJ. Sithole
Sherwood Forest Hospitals Foundation Trust and Academic Unit of Diabetes, Endocrinology and Metabolism, University of Sheffield, Sheffield and Trent RDSU, University of Nottingham, Nottingham, UK
2 shared publicationsRamalingam Srinivasan
Department of Diabetes & Endocrinology, Nottingham City Hospital, Nottingham, UK
2 shared publicationsRenee C. Page
Department of Diabetes & Endocrinology, Nottingham City Hospital, Nottingham, UK
2 shared publications
Latest Publications
- Open Access
- 19 June 2020
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 22 (7) , 1226-1228
News and Views July 2020
- 19 June 2020
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 22 (7) , 1226-1228
Open AccessNews and Views July 2020
- Open Access
- 26 April 2020
- Published by Wiley in Diabetes, Obesity and Metabolism Now
- Vol. 1 (1)
Diabetes, obesity and metabolism news and views, April 2020
- 26 April 2020
- Published by Wiley in Diabetes, Obesity and Metabolism Now
- Vol. 1 (1)
Open AccessDiabetes, obesity and metabolism news and views, April 2020
- Open Access
- 1 April 2020
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 22 (5) , 885-887
News and Views May 2020
- 1 April 2020
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 22 (5) , 885-887
Open AccessNews and Views May 2020
- Open Access
- 17 February 2020
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 22 (3) , 463-465
News and Views March 2020
- 17 February 2020
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 22 (3) , 463-465
Open AccessNews and Views March 2020
- Open Access
- 3 December 2019
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 22 (1) , 135-137
News and Views January 2020: Highlights from the European Association of the Study of Diabetes (EASD) Scientific Meeting 2019
- 3 December 2019
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 22 (1) , 135-137
Open AccessNews and Views January 2020: Highlights from the European Association of the Study of Diabetes (EASD) Scientific Meeting 2019
- Open Access
- 17 October 2019
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 21 (11) , 2582-2584
News and Views November 2019
- 17 October 2019
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 21 (11) , 2582-2584
Open AccessNews and Views November 2019
- Open Access
- 1 November 2016
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 121, 69-85
Comparison of cardiovascular and metabolic outcomes in people with type 2 diabetes on insulin versus non-insulin glucose-lowering therapies (GLTs): A systematic review and meta-analysis of clinical trials
- 1 November 2016
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 121, 69-85
Open AccessComparison of cardiovascular and metabolic outcomes in people with type 2 diabetes on insulin versus non-insulin glucose-lowering therapies (GLTs): A systematic review and meta-analysis of clinical trials
- 4 April 2013
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 15 (10) , 882-887
The use of U‐500 regular insulin in the management of patients with obesity and insulin resistance
The rise in prevalence of obesity and diabetes has created a challenge in managing increasing numbers of patients who require high doses of insulin. This article reviews the published literature on the properties of U‐500 insulin and its use in clinical practice. U‐500 insulin is likely to have a longer time to peak effect and a longer duration of action than similar doses of U‐100 insulin. Evidence for its use in clinical practice rests on retrospective case series, which suggests that the use of U‐500 insulin either by multiple daily injections or a continuous subcutaneous insulin infusion is effective in improving glycaemic control. To prevent insulin dosing and administration errors, great care must be taken in providing staff and patient education, and in developing policies for the management of patients on U‐500 insulin who are admitted to hospital.
- 4 April 2013
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 15 (10) , 882-887
The use of U‐500 regular insulin in the management of patients with obesity and insulin resistance
The rise in prevalence of obesity and diabetes has created a challenge in managing increasing numbers of patients who require high doses of insulin. This article reviews the published literature on the properties of U‐500 insulin and its use in clinical practice. U‐500 insulin is likely to have a longer time to peak effect and a longer duration of action than similar doses of U‐100 insulin. Evidence for its use in clinical practice rests on retrospective case series, which suggests that the use of U‐500 insulin either by multiple daily injections or a continuous subcutaneous insulin infusion is effective in improving glycaemic control. To prevent insulin dosing and administration errors, great care must be taken in providing staff and patient education, and in developing policies for the management of patients on U‐500 insulin who are admitted to hospital.
- 8 December 2012
- Published by Wiley in Diabetic Medicine
- Vol. 30 (3) , e95-e100
Responders to insulin therapy at 18 months in adults with newly diagnosed diabetes: which insulin regimen?
Objectives To describe baseline characteristics of responders to insulin therapy (HbA1c targets < 58 mmol/mol, 7.5%) at 18 months among adults with newly diagnosed diabetes. Methods A retrospective UK study derived from 479 general practices electronic dataset. We included all adults (age > 18 years) with newly diagnosed diabetes who required insulin therapy within 6 months of diagnosis. The data comprised insulin regimen (long-acting only; premixed insulin only; basal bolus insulin regimen), gender, Townsend quintile, baseline and an 18-month measurement of clinical and biochemical variables. Multiple imputations were undertaken and logistic regression used to assess the effect of covariates. Results A total of 1492 patients (aged 19–93 years) were analysed. Means (SD) baseline HbA1c and BMI were 10.3% (2.6%) and 29.6 (7.0%), respectively. Following multiple imputation for missing data, logistic regression analysis indicated important covariates to achieve HbA1c targets were baseline HbA1c, lipid lowering therapy, gender and age. Including all covariates, those treated with premixed insulin were 47% more likely to achieve target HbA1c at 18 months than those treated with a basal-bolus regimes (adjusted OR 1.47; 95% CI 1.12–1.92, P = 0.006)) and 32% more likely than those treated with long-acting insulin was (adjusted OR 1.32; 95% CI 1.01–1.74, P = 0.044). Those with a higher baseline HbA1c level, on lipid-lowering therapy, women and younger patients had a lower response rate. Mean weight gain (SD) was 2.4 kg (8.5 kg) and was not influenced by treatment regimen. Conclusion The use of premixed insulin regimen among newly diagnosed patients with diabetes appears to be most effective in reaching HbA1c target values, independent of other confounders. The appropriate choice of insulin regimen at initiation should therefore take into account various metabolic and psychosocial factors.
- 8 December 2012
- Published by Wiley in Diabetic Medicine
- Vol. 30 (3) , e95-e100
Responders to insulin therapy at 18 months in adults with newly diagnosed diabetes: which insulin regimen?
Objectives To describe baseline characteristics of responders to insulin therapy (HbA1c targets < 58 mmol/mol, 7.5%) at 18 months among adults with newly diagnosed diabetes. Methods A retrospective UK study derived from 479 general practices electronic dataset. We included all adults (age > 18 years) with newly diagnosed diabetes who required insulin therapy within 6 months of diagnosis. The data comprised insulin regimen (long-acting only; premixed insulin only; basal bolus insulin regimen), gender, Townsend quintile, baseline and an 18-month measurement of clinical and biochemical variables. Multiple imputations were undertaken and logistic regression used to assess the effect of covariates. Results A total of 1492 patients (aged 19–93 years) were analysed. Means (SD) baseline HbA1c and BMI were 10.3% (2.6%) and 29.6 (7.0%), respectively. Following multiple imputation for missing data, logistic regression analysis indicated important covariates to achieve HbA1c targets were baseline HbA1c, lipid lowering therapy, gender and age. Including all covariates, those treated with premixed insulin were 47% more likely to achieve target HbA1c at 18 months than those treated with a basal-bolus regimes (adjusted OR 1.47; 95% CI 1.12–1.92, P = 0.006)) and 32% more likely than those treated with long-acting insulin was (adjusted OR 1.32; 95% CI 1.01–1.74, P = 0.044). Those with a higher baseline HbA1c level, on lipid-lowering therapy, women and younger patients had a lower response rate. Mean weight gain (SD) was 2.4 kg (8.5 kg) and was not influenced by treatment regimen. Conclusion The use of premixed insulin regimen among newly diagnosed patients with diabetes appears to be most effective in reaching HbA1c target values, independent of other confounders. The appropriate choice of insulin regimen at initiation should therefore take into account various metabolic and psychosocial factors.
- Open Access
- 9 July 2012
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 172 (13) , 1005-1011
Association Between Thiazolidinedione Treatment and Risk of Macular Edema Among Patients With Type 2 Diabetes
The thiazolidinediones, pioglitazone and rosiglitazone, are peroxisome proliferator–activated receptor γ (PPAR-γ) agonists that ameliorate peripheral and hepatic insulin resistance and are effective glucose-lowering treatments for patients with type 2 diabetes mellitus.1 The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommend thiazolidinediones as second- or third-line therapy in combination with other oral agents or insulin to achieve target levels of glycemic control.2 The risk-benefit ratio for thiazolidinedione use has been the subject of intense discussion following a series of metabolic and cardiovascular outcome studies.3,4 Several analyses have highlighted the major adverse effects of thiazolidinediones, including an increased incidence of bone fractures,5 fluid retention and edema,6 increased risk of heart failure,7 and, more recently, potentially increased risk of bladder cancer.8
- 9 July 2012
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 172 (13) , 1005-1011
Open AccessAssociation Between Thiazolidinedione Treatment and Risk of Macular Edema Among Patients With Type 2 Diabetes
The thiazolidinediones, pioglitazone and rosiglitazone, are peroxisome proliferator–activated receptor γ (PPAR-γ) agonists that ameliorate peripheral and hepatic insulin resistance and are effective glucose-lowering treatments for patients with type 2 diabetes mellitus.1 The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommend thiazolidinediones as second- or third-line therapy in combination with other oral agents or insulin to achieve target levels of glycemic control.2 The risk-benefit ratio for thiazolidinedione use has been the subject of intense discussion following a series of metabolic and cardiovascular outcome studies.3,4 Several analyses have highlighted the major adverse effects of thiazolidinediones, including an increased incidence of bone fractures,5 fluid retention and edema,6 increased risk of heart failure,7 and, more recently, potentially increased risk of bladder cancer.8